Bexarotene-induced hypothyroidism and dyslipidemia; a nation-wide study

• DOI: 10.1507/endocrj.ej23-0699
• Publication Date: 2024-06-04T22:11:07Z
• Authors: Katsunori Manaka; Junichiro Sato; Yusuke Hikima; Hirofumi Horikoshi; Maho Taguchi; Akimichi Morita; Hiraku Suga; Hikari Boki; Taku Fujimura; Yoji Hirai; Takatoshi Shimauchi; Chiharu Tateishi; Eiji Kiyohara; Ikko Muto; Hideki Nakajima; Riichiro Abe; Kazuyasu Fujii; Chikako Nishigori; Eiji Nakano; Kentaro Yonekura; Takeru Funakoshi; Masahiro Amano; Tomomitsu Miyagaki; Reiko Yamashita; Makoto Sugaya; Toshihisa Hamada; Masaomi Nangaku; Taroh Iiri; Noriko Makita
• Keywords: Bexarotene; Dyslipidemia; Lipid Profile

Central hypothyroidism and dyslipidemia are well-known adverse events (AEs) of bexarotene therapy. Although is known to cause dyslipidemia, no study has examined the association between in patients undergoing The aim this examine association. A retrospective observational was performed among 294 who initiated therapy Japan (nation-wide postmarketing complete surveillance). Jonckheere-Terpstra (one sided) test evaluate effect dose on lipid metabolisms, regression analyses were associations dose, free thyroxine (FT4), body mass index (BMI), metabolisms. Most developed hypothyroidism. Two-third showed FT4 values below lower limit at 1 week. Triglycerides (TG) increased a dose–dependent manner, grade ≥3 AEs hypertriglyceridemia observed 39% patients. Additionally, one-third occurred within delta_FT4 (difference from baseline) negatively correlated with TG increase week (p = 0.012) but not low density lipoprotein cholesterol (LDL-C) any Bexarotene-induced almost inevitable quickly. positive dependency negative dependency. Prophylactic appropriate thyroid hormone compensation starting doses subsequent titration while managing may have beneficial for successful continuation without severe endocrine metabolic AEs.